^
Association details:
| Biomarker: | MET amplification + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-140 - MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Published date:
07/12/2022
Excerpt:
SAVANNAH is a single-arm, PhII study in which patients with EGFRm NSCLC who have MET overexpression and/or amplification upon disease progression post-osimertinib received oral savolitinib 300/600mg once-daily (QD) or 300mg twice-daily, in combination with oral osimertinib 80mg QD....Efficacy in the IHC90+ and/or FISH10+ subgroup (ORR 49%, median DoR 9.3 months, median PFS 7.1 months) was improved compared to the overall population; particularly versus the subgroup without IHC90+ and/or FISH10+ status (ORR 9%, median DoR 6.9 months, median PFS 2.8 months) (Table).
Trial ID:
Source:
Title:
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model
Published date:
05/04/2023
Excerpt:
A patient-derived xenograft (PDX) mouse model with EGFRm, MET-amplified NSCLC was tested with a fixed osimertinib dose [10 mg/kg for exposures equivalent to (≈)80 mg], combined with doses of savolitinib (0–15 mg/kg, ≈0–600 mg once daily)....Upon combination, at a fixed dose of osimertinib, significant savolitinib dose-related antitumor activity was shown, ranging from 81% TGI (0.3 mg/kg) to 84% tumor regression (15 mg/kg)…. Savolitinib demonstrated exposure-related combination antitumor activity when combined with osimertinib in the EGFRm MET-amplified NSCLC PDX model.
DOI:
10.1158/1535-7163.MCT-22-0193
